|
1
|
López-Otín C and Matrisian LM: Emerging
roles of proteases in tumor suppression. Nat Rev Cancer. 7:800–808.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Rawlings ND, Barrett AJ and Bateman A:
MEROPS: The database of proteolytic enzymes, their substrates and
inhibitors. Nucleic Acids Res. 40 (Database Issue):D343–D350.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tan GJ, Peng ZK, Lu JP and Tang FQ:
Cathepsins mediate tumor metastasis. World J Biol Chem. 4:91–101.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gocheva V, Zeng W, Ke D, Klimstra D,
Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for
cysteine cathepsin genes in multistage tumorigenesis. Genes Dev.
20:543–556. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Turk B, Turk D and Turk V: Protease
signalling: The cutting edge. EMBO J. 31:1630–1643. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Repnik U, Starr AE, Overall CM and Turk B:
Cysteine cathepsins activate ELR chemokines and inactivate non-ELR
chemokines. J Biol Chem. 290:13800–13811. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wilkinson RD, Magorrian SM, Williams R,
Young A, Small DM, Scott CJ and Burden RE: CCL2 is
transcriptionally controlled by the lysosomal protease cathepsin S
in a CD74 dependent manner. Oncotarget. 6:29725–29739.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Joyce JA, Baruch A, Chehade K, Meyer-Morse
N, Giraudo E, Tsai FY, Greenbaum DC, Hager JH, Bogyo M and Hanahan
D: Cathepsin cysteine proteases are effectors of invasive growth
and angiogenesis during multistage tumorigenesis. Cancer Cell.
5:443–453. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
National Comprehensive Cancer Network:
Gastric cancer. NCCN clinical practice guidelines in oncology.
Version 2.2018, May 22, 2018.
|
|
10
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108.
2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Crew KD and Neugut AI: Epidemiology of
gastric cancer. World J Gastroenterol. 12:354–362. 2006.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mohanty S and Panda KS: Gastric cancer in
young patients under the age of 35 years: A hospital-based study.
Int Surg J. 3:1933–1936. 2016. View Article : Google Scholar
|
|
13
|
Egger ME, Ikoma N and Badgwell BD: Primary
gastric malignancies. In: Feig BW Ching CD (eds). The MD Anderson
Surgical Oncology Handbook. 6th edition. Philadelphia. Worters
Kluwer. pp379–431. 2019.
|
|
14
|
Ahn HJ and Lee DS: Helicobacter
pylori in gastric carcinogenesis. World J Gastrointest Oncol.
7:455–465. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490.
2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bae JM and Kim EH: Helicobacter
pylori infection and risk of gastric cancer in Korea: A
quantitative systematic review. J Prev Med Public Health.
49:197–204. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Amedei A, Munari F, Bella CD, Niccolai E,
Benagiano M, Bencini L, Cianchi F, Farsi M, Emmi G, Zanotti G, et
al: Helicobacter pylori secreted peptidyl prolyl cis,
trans-isomerase drives Th17 inflammation in gastric adenocarcinoma.
Intern Emerg Med. 9:303–309. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Carneiro F, Machado JC, David L, Reis C,
Nogueira AM and Sobrinho-Simões M: Current thoughts on the
histopathogenesis of gastric cancer. Eur J Cancer Prev. 10:101–102.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Scartozzi M, Galizia E, Freddari F,
Berardi R, Cellerino R and Cascinu S: Molecular biology of sporadic
gastric cancer: Prognostic indicators and novel therapeutic
approaches. Cancer Treat Rev. 30:451–459. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lynch HT, Grady W, Suriano G and Huntsman
D: Gastric cancer: New genetic developments. J Surg Oncol.
90:114–133. 2005.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kono K, Takahashi A, Ichihara F, Sugai H,
Fujii H and Matsumoto Y: Impaired antibody-dependent cellular
cytotoxicity mediated by herceptin in patients with gastric cancer.
Cancer Res. 62:5813–5817. 2002.PubMed/NCBI
|
|
22
|
Doi T, Koizumi W, Siena S, Cascinu S,
Ohtsu A and Michael M: Efficacy, tolerability and pharmacokinetics
of gefinitib (ZD1839) in pretreated patients with metastatic
gastric cancer. Proc Am Soc Clin Oncol. 22(Abstr 1036)2003.
|
|
23
|
Shi GP, Sukhova GK, Kuzuya M, Ye Q, Du J,
Zhang Y, Pan JH, Lu ML, Cheng XW, Iguchi A, et al: Deficiency of
the cysteine protease cathepsin S impairs microvessel growth. Circ
Res. 92:493–500. 2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vázquez R, Astorgues-Xerri L, Bekradda M,
Gormley J, Buick R, Kerr P, Cvitkovic E, Raymond E, D'Incalci M,
Frapolli R and Riveiro ME: Fsn0503h antibody-mediated blockade of
cathepsin S as a potential therapeutic strategy for the treatment
of solid tumors. Biochimie. 108:101–107. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Burden RE, Gormley JA, Jaquin TJ, Small
DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA
and Scott CJ: Antibody-mediated inhibition of cathepsin S blocks
colorectal tumor invasion and angiogenesis. Clin Cancer Res.
15:6042–6051. 2009.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Burden RE, Gormley JA, Kuehn D, Ward C,
Kwok HF, Gazdoiu M, McClurg A, Jaquin TJ, Johnston JA, Scott CJ and
Olwill SA: Inhibition of cathepsin S by Fsn0503 enhances the
efficacy of chemotherapy in colorectal carcinomas. Biochemie.
94:487–493. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang L, Wang H and Xu J: Cathepsin S as a
cancer target. Neoplasma. 62:16–26. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sevenich L, Bowman RL, Mason SD, Quail DF,
Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ,
et al: Analysis of tumour- and stroma-supplied proteolytic networks
reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell
Biol. 16:876–888. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Huang CC, Chen KL, Cheung CHA and Chang
JY: Autophagy induced by cathepsin S inhibition induces early ROS
production, oxidative DNA damage, and cell death via xanthine
oxidase. Free Radic Biol Med. 65:1473–1486. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Small DM, Burden RE, Jaworski J, Hegarty
SM, Spence S, Burrows JF, McFarlane C, Kissenpfennig A, McCarthy
HO, Johnston JA, et al: Cathepsin S from both tumor and
tumor-associated cells promote cancer growth and
neovascularization. Int J Cancer. 133:2102–2112. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Liu WL, Liu D, Cheng K, Liu YJ, Xing S,
Chi PD, Liu XH, Xue N, Lai YZ, Guo L and Zhang G: Evaluating the
diagnostic and prognostic value of circulating cathepsin S in
gastric cancer. Oncotarget. 7:28124–28138. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Kwok HF, Buick RJ, Kuehn D, Gormley JA,
Doherty D, Jaquin TJ, McClurg A, Ward C, Byrne T, Jaworski J, et
al: Antibody targeting of Cathepsin S induces antibody-dependent
cellular cytotoxicity. Mol Cancer. 10(147)2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yang Y, Lim SK, Choong LY, Lee H, Chen Y,
Chong PK, Ashktorab H, Wang TT, Salto-Tellez M, Yeoh KG and Lim YP:
Cathepsin S mediates gastric cancer cell migration and invasion via
a putative network of metastasis-associated proteins. J Proteome
Res. 9:4767–4778. 2010.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Turk V, Turk B and Turk D: Lysosomal
cysteine proteases: Facts and opportunities. EMBO J. 20:4629–4633.
2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Jordans S, Jenko-Kokalj S, Kuhl NM,
Tedelind S, Sendt W, Bromme D, Turk D and Brix K: Monitoring
compartment-specific substrate cleavage by cathepsins B, K, L, and
S at physiological pH and redox conditions. BMC Biochem.
10(23)2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Turk V, Stoka V, Vasiljeva O, Renko M, Sun
T, Turk B and Turk D: Cysteine cathepsins: From structure, function
and regulation to new frontiers. Biochim Biophys Acta. 1824:68–88.
2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang B, Sun J, Kitamoto S, Yang M, Grubb
A, Chapman HA, Kalluri R and Shi GP: Cathepsin S controls
angiogenesis and tumor growth via matrix-derived angiogenic
factors. J Biol Chem. 281:6020–6029. 2006.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee TK, Cheung VC, Lu P, Lau EY, Ma S,
Tang KH, Tong M, Lo J and Ng IO: Blockade of CD47-mediated
cathepsin S/protease-activated receptor 2 signaling provides a
therapeutic target for hepatocellular carcinoma. Hepatology.
60:179–191. 2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wang X, Xiong L, Yu G, Li D, Peng T, Luo D
and Xu J: Cathepsin S silencing induces apoptosis of human
hepatocellular carcinoma cells. Am J Transl Res. 19:100–110.
2015.PubMed/NCBI
|
